534 Responses to immunotherapy based on programmed death-ligand 1 (PD-L1) copy number variation (CNV) status in patients with advanced non-small cell lung cancer (NSCLC)

• Kaushal Parikh,
• Aakash Desai,
• Julian Molina,
• Aaron Mansfield,
• Konstantinos Leventakos,
• Julia Naso,
• Caleb Smith,
• Yash Ashara,
• Beth Pitel,
• Anastasios Dimou,
• Ying-Chun Lo

Affiliations

Kaushal Parikh

Mayo Clinic, Rochester, MN, USA

Aakash Desai

Mayo Clinic, Rochester, MN, USA

Julian Molina

Mayo Clinic, Rochester, MN, USA

Aaron Mansfield

Mayo Clinic, Rochester, MN, USA

Konstantinos Leventakos

Mayo Clinic, Rochester, MN, USA

Julia Naso

Mayo Clinic, Rochester, MN, USA

Caleb Smith

Mayo Clinic, Rochester, MN, USA

Yash Ashara

Mayo Clinic, Rochester, MN, USA

Beth Pitel

Mayo Clinic, Rochester, MN, USA

Anastasios Dimou

Mayo Clinic, Rochester, MN, USA

Ying-Chun Lo

Mayo Clinic, Rochester, MN, USA